azathioprine has been researched along with Demyelinating Diseases in 21 studies
Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed)
azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| " No other serious adverse events were reported for these treatments." | 2.72 | Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis. ( Gao, F; Hao, H; Jin, H; Jin, Y; Liu, R; Lu, Q; Luo, J, 2021) |
| "Demyelination is similar with malignancy in clinical symptoms." | 1.72 | Astrocytoma with myelin oligodendrocyte glycoprotein antibody associated encephalomyelitis: A case report. ( Gu, H; Liu, X; Yang, S; Zhang, J; Zhong, G, 2022) |
| "Azathioprine was the treatment prescribed in the four patients with NMOSD." | 1.51 | Inflammatory demyelinating diseases of the central nervous system in Niger. ( Adehossi Omar, É; Assadeck, H; Douma Maiga, D; Hassane Djibo, F; Mamadou, Z; Toudou Daouda, M, 2019) |
| "Prednisone use was associated with higher mortality [HR = 3." | 1.46 | Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy. ( Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017) |
| " In spite of the temporary remission after re-initiation of oral steroid therapy, reduction of oral steroid dosage resulted in new lesion formation apart from the initial locations." | 1.43 | An adult-onset multiphasic disseminated encephalomyelitis (MDEM) presenting favorable response to steroid therapy. ( Fujimura, H; Fukada, K; Hazama, T; Inoue, K; Kinoshita, M; Sugimura, Y, 2016) |
| "In conclusion, CIDP is a clinically heterogeneous disorder." | 1.34 | Chronic inflammatory demyelinating polyneuropathy: a 6-year retrospective clinical study of a hospital-based population. ( Anyfanti, C; Ioannou, M; Kaponi, A; Pandis, D; Rentzos, M; Vassilopoulos, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (33.33) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 3 (14.29) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Zhong, G | 1 |
| Zhang, J | 1 |
| Liu, X | 1 |
| Yang, S | 1 |
| Gu, H | 1 |
| George, IC | 1 |
| Kvalsund, M | 1 |
| Saylor, D | 1 |
| Lu, Q | 1 |
| Luo, J | 1 |
| Hao, H | 1 |
| Liu, R | 1 |
| Jin, H | 1 |
| Jin, Y | 1 |
| Gao, F | 1 |
| Assadeck, H | 1 |
| Toudou Daouda, M | 1 |
| Adehossi Omar, É | 1 |
| Mamadou, Z | 1 |
| Hassane Djibo, F | 1 |
| Douma Maiga, D | 1 |
| Sugimura, Y | 1 |
| Kinoshita, M | 1 |
| Fukada, K | 1 |
| Inoue, K | 1 |
| Fujimura, H | 1 |
| Hazama, T | 1 |
| D'Haens, G | 1 |
| Reinisch, W | 1 |
| Colombel, JF | 1 |
| Panes, J | 1 |
| Ghosh, S | 1 |
| Prantera, C | 1 |
| Lindgren, S | 1 |
| Hommes, DW | 1 |
| Huang, Z | 1 |
| Boice, J | 1 |
| Huyck, S | 1 |
| Cornillie, F | 1 |
| Rentzos, M | 1 |
| Anyfanti, C | 1 |
| Kaponi, A | 1 |
| Pandis, D | 1 |
| Ioannou, M | 1 |
| Vassilopoulos, D | 1 |
| Streib, EW | 1 |
| Sun, SF | 1 |
| Louboutin, JP | 1 |
| Elie, B | 1 |
| Krendel, DA | 1 |
| Costigan, DA | 1 |
| Hopkins, LC | 1 |
| Nakamura, M | 1 |
| Fuchinoue, S | 1 |
| Sato, S | 1 |
| Hoshino, T | 1 |
| Sawada, T | 1 |
| Sageshima, J | 1 |
| Kitajima, K | 1 |
| Tojinbara, T | 1 |
| Fujita, S | 1 |
| Nakajima, I | 1 |
| Agishi, T | 1 |
| Tanaka, K | 1 |
| Mancuso, A | 1 |
| Ardita, FV | 1 |
| Leonardi, J | 1 |
| Scuderi, M | 1 |
| Baba, M | 1 |
| Matsunaga, M | 1 |
| Oh, SJ | 1 |
| Joy, JL | 1 |
| Sunwoo, I | 1 |
| Kuruoglu, R | 1 |
| Jakobsen, J | 1 |
| Krarup, C | 1 |
| Barrowman, JA | 1 |
| Kutty, PK | 1 |
| Ra, MU | 1 |
| Huang, SN | 1 |
| Kiprov, DD | 1 |
| Miller, RG | 1 |
| Dyck, PJ | 1 |
| O'Brien, P | 1 |
| Swanson, C | 1 |
| Low, P | 1 |
| Daube, J | 1 |
| Schneck, SA | 1 |
| Ulrich, J | 1 |
| Wüthrich, R | 1 |
| Manz, HJ | 1 |
| Dinsdale, HB | 1 |
| Morrin, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Crohn's Disease European Registry. A Prospective, Observational, Postmarketing Safety Surveillance Registry of Patients Treated With Remicade® or Standard Therapy[NCT00705614] | 2,662 participants (Actual) | Observational | 2003-07-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The number of participant fatalities was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 30 |
| Standard Therapy | 14 |
| Switched to Remicade | 4 |
The number of participants with demyelinating neurological disorders was evaluated. Demyelinating neurological disorders were defined as multiple sclerosis, optic neuritis, peripheral syndromes such as peripheral neuropathy, mononeuropathy multipex, cranial neuropathies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyradiculoneuropathy, and transverse myelitis. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 4 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants wtih hematologic conditions was evaluated. A hematologic condition was defined as thrombocytopenia, neutropenia, pancytopenia, granulocytopenia, leukopenia, or aplastic anemia. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 50 |
| Standard Therapy | 11 |
| Switched to Remicade | 7 |
The number of participants with infusion-related reactions and/or hypersensitivity was evaluated. An infuson-related reaction/hypersensitivity was defined as as an acute reaction, including anaphylactic shock that occurs after the onset of the infusion or within the 1- to 2-hour observation period following the end of the infusion. Delayed hypersensitivity reactions (myalgia and/or arthralgia with fever and rash within 14 days of the infusion) were included. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 173 |
| Standard Therapy | 1 |
| Switched to Remicade | 28 |
The number of participants wtih lymphoproliferative disorders and/or malignancies was evaluated. A lymphoproliferative disorder and /or malignancy included, but was not limited to, lymphoma, gastrointestinal cancer, skin cancer (including basocellular and squamous carcinoma, melanoma) and in situ cervical carcinoma. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 49 |
| Standard Therapy | 21 |
| Switched to Remicade | 8 |
The number of participants with new or worsening congestive heart failure was evaluated throughout the study. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 1 |
| Standard Therapy | 1 |
| Switched to Remicade | 0 |
The number of participants experiencing serious infections was evaluated. Serious infections included, but were not limited to, tuberculosis, opportunistic infections (such as Pneumocystis carinii [PCP] pneumonia, listeriosis, atypical mycobacteria, and histoplasmosis), salmonellosis,and serious viral infections. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) |
|---|---|
| Remicade | 132 |
| Standard Therapy | 47 |
| Switched to Remicade | 18 |
The duration of hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Days (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=657,418 ,0) | Visit 2 (n=304,126, 33) | Visit 3 (n=216, 58, 35) | Visit 4 (n=151, 60, 24) | Visit 5 (n=105, 35, 34) | Visit 6 (n=107, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=80, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 12.2 | 14.4 | 14.2 | 12.6 | 11.7 | 10.8 | 10.6 | 9.5 | 12.4 | 10.1 | 11.4 |
| Standard Therapy | 10.8 | 12.0 | 9.4 | 8.5 | 9.8 | 13.7 | 10.2 | 16.3 | 6.9 | 8.0 | 8.7 |
| Switched to Remicade | NA | 13.0 | 13.5 | 9.1 | 7.1 | 18.3 | 10.0 | 14.7 | 10.7 | 9.0 | 18.1 |
The number of participant hospital stays for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Hospital Stays (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1539, 1121, 0) | Visit 2 (n=1418, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1170, 665, 208) | Visit 7 (n=1111, 615, 219) | Visit 8 (n=1099, 589, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1031, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 0.7 | 0.3 | 0.3 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Standard Therapy | 0.5 | 0.2 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Switched to Remicade | NA | 0.5 | 0.4 | 0.2 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
The number of participants undergoing surgical procedures for Crohn's Disease in the prior 6 months was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Surgical Procedures (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Basline; n=660, 419, 0) | Visit 2 (n=304, 126, 33) | Visit 3 (n=217, 57, 36) | Visit 4 (n=153, 60, 24) | Visit 5 (n=106, 36, 34) | Visit 6 (n=108, 49, 19) | Visit 7 (n=109, 45, 25) | Visit 8 (n=98, 29, 23) | Visit 9 (n=82, 38, 17) | Visit 10 (n=85, 29, 27) | Visit 11 (n=63, 19, 18) | |
| Remicade | 171 | 135 | 121 | 68 | 50 | 49 | 48 | 43 | 38 | 38 | 34 |
| Standard Therapy | 81 | 51 | 23 | 16 | 14 | 21 | 20 | 12 | 13 | 13 | 6 |
| Switched to Remicade | NA | 7 | 12 | 8 | 14 | 11 | 6 | 7 | 8 | 8 | 8 |
The number of participants with a draining fistula was evaluated at each study visit. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1541, 1120, 0) | Visit 2 (n=1420, 920, 100) | Visit 3 (n=1334, 827, 152) | Visit 4 (n=1285, 779, 168) | Visit 5 (n=1221, 714, 188) | Visit 6 (n=1169, 666, 208) | Visit 7 (n=1110, 615, 219) | Visit 8 (n=1097, 588, 233) | Visit 9 (n=1046, 562, 229) | Visit 10 (n=1030, 535, 235) | Visit 11 (n=1006, 541, 248) | |
| Remicade | 349 | 211 | 170 | 146 | 125 | 114 | 97 | 105 | 98 | 85 | 87 |
| Standard Therapy | 96 | 51 | 41 | 31 | 29 | 26 | 31 | 23 | 32 | 15 | 16 |
| Switched to Remicade | NA | 16 | 19 | 12 | 15 | 15 | 15 | 16 | 15 | 20 | 20 |
The participant assessment of overall health status was evaluated at baseline and each study visit. The overall health status questionnaire asked participants to rate their current health status over the prior 24 hours as 1=best possible, 2=much better than average, 3=better than average, 4=average, 5=worse than average, 6=much worse than average, or 7=worst possible. Scores ranged from 1 to 7 with lower scores indicating better health status. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1526, 1116, 0) | Visit 2 (n=1344, 903, 95) | Visit 3 (n=1280, 809, 146) | Visit 4 (n=1217, 755, 162) | Visit 5 (n=1160, 704, 184) | Visit 6 (n=1110, 649, 202) | Visit 7 (n=1046, 606, 212) | Visit 8 (n=1044, 573, 221) | Visit 9 (n=999, 544, 223) | Visit 10 (n=963, 520, 227) | Visit 11 (n=956, 527, 235) | |
| Remicade | 4.3 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 | 3.1 | 3.1 | 3.1 | 3.0 | 3.0 |
| Standard Therapy | 3.9 | 3.3 | 3.1 | 3.0 | 3.1 | 3.0 | 3.0 | 3.0 | 2.9 | 2.8 | 2.8 |
| Switched to Remicade | NA | 3.9 | 3.6 | 3.5 | 3.2 | 3.4 | 3.3 | 3.2 | 3.2 | 3.1 | 3.1 |
The Harvey-Bradshaw Index of Crohn's Disease Acitivity was evaluated at each study visit. The Harvey-Bradshaw Index evaluates participants' general health in the day prior in the domains of well being, abdominal pain, number of liquid stools per day, and abdominal mass and complications and was evaluated on the day of the study visit. The score is derived from a 0-4 score for general well being, 0-3 for abdmonial pain, raw score for number of liquid stools per day, 0-3 for abdominal mass, and raw score for complications. The total score is from 0 to infinity, with lower scores indicating better outcomes. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1505, 1106, 0) | Visit 2 (n=1320, 876, 91) | Visit 3 (n=1250, 785, 143) | Visit 4 (n=1196, 742, 159) | Visit 5 (n=1127, 692, 181) | Visit 6 (n=1070, 647, 199) | Visit 7 (n=1023, 592, 209) | Visit 8 (n=1015, 562, 224) | Visit 9 (n=953, 546, 219) | Visit 10 (n=936, 526, 225) | Visit 11 (n=918, 525, 238) | |
| Remicade | 8.2 | 4.1 | 3.7 | 3.8 | 3.7 | 3.6 | 3.6 | 3.6 | 3.6 | 3.4 | 3.4 |
| Standard Therapy | 6.2 | 3.8 | 3.5 | 3.2 | 3.4 | 3.1 | 3.0 | 3.2 | 2.9 | 2.7 | 2.7 |
| Switched to Remicade | NA | 6.0 | 4.4 | 4.8 | 4.9 | 4.5 | 4.1 | 4.1 | 4.4 | 4.3 | 4.2 |
The participant work/daily activity status score was evaluated at each study visit. The work/daily activity questionnaire asked participants to rate their level of daily functioning on a scale of 1 to 10 with a lower score indicating less of an impact of Crohn's disease on work or daily life functioning. (NCT00705614)
Timeframe: Up to 5 Years
| Intervention | Score on a Scale (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Visit 1 (Baseline; n=1496, 1108, 0) | Visit 2 (n=1316, 895, 94) | Visit 3 (n=1235, 797, 143) | Visit 4 (n=1192, 738, 159) | Visit 5 (n=1128, 694, 179) | Visit 6 (n=1077, 638, 201) | Visit 7 (n=1030, 601, 207) | Visit 8 (n=1025, 571, 221) | Visit 9 (n=982, 542, 222) | Visit 10 (n=934, 514, 225) | Visit 11 (n=925, 521, 235) | |
| Remicade | 5.9 | 4.2 | 3.8 | 3.6 | 3.4 | 3.3 | 3.2 | 3.3 | 3.3 | 3.1 | 3.2 |
| Standard Therapy | 4.9 | 3.7 | 3.2 | 2.9 | 3.0 | 2.7 | 2.8 | 2.7 | 2.6 | 2.4 | 2.4 |
| Switched to Remicade | NA | 5.5 | 4.8 | 4.3 | 4.0 | 3.9 | 3.6 | 3.5 | 3.5 | 3.6 | 3.6 |
2 reviews available for azathioprine and Demyelinating Diseases
| Article | Year |
|---|---|
Efficacy and safety of long-term immunotherapy in adult patients with MOG antibody disease: a systematic analysis.
Topics: Adult; Autoantibodies; Azathioprine; Demyelinating Diseases; Humans; Immunologic Factors; Immunother | 2021 |
[Chronic inflammatory demyelinating polyneuropathy: multifocal demyelinating neuropathy].
Topics: Adolescent; Adult; Aged; Azathioprine; Child; Chronic Disease; Demyelinating Diseases; Female; Human | 1992 |
1 trial available for azathioprine and Demyelinating Diseases
| Article | Year |
|---|---|
Combined azathioprine and prednisone in chronic inflammatory-demyelinating polyneuropathy.
Topics: Adult; Aged; Azathioprine; Demyelinating Diseases; Drug Combinations; Female; Humans; Male; Middle A | 1985 |
18 other studies available for azathioprine and Demyelinating Diseases
| Article | Year |
|---|---|
Astrocytoma with myelin oligodendrocyte glycoprotein antibody associated encephalomyelitis: A case report.
Topics: Aquaporin 4; Astrocytoma; Autoantibodies; Azathioprine; Demyelinating Diseases; Dizziness; Encephalo | 2022 |
A case of combined central and peripheral demyelination in Zambia.
Topics: Adult; Azathioprine; Comorbidity; Demyelinating Diseases; Developing Countries; Glucocorticoids; Hum | 2020 |
Inflammatory demyelinating diseases of the central nervous system in Niger.
Topics: Adult; Aged; Azathioprine; Central Nervous System Diseases; Demyelinating Diseases; Disability Evalu | 2019 |
An adult-onset multiphasic disseminated encephalomyelitis (MDEM) presenting favorable response to steroid therapy.
Topics: Administration, Oral; Azathioprine; Brain; Demyelinating Diseases; Diagnosis, Differential; Drug The | 2016 |
Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents; Azathio | 2017 |
Chronic inflammatory demyelinating polyneuropathy: a 6-year retrospective clinical study of a hospital-based population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Biopsy; Demyelinating Diseases; Female; Gr | 2007 |
Acquired demyelinative polyneuropathy: diagnosis and treatment with special reference to immunosuppressive therapy.
Topics: Adult; Azathioprine; Demyelinating Diseases; Female; Humans; Immunosuppressive Agents; Male; Middle | 1984 |
Treatment of Balo's concentric sclerosis with immunosuppressive drugs followed by multimodality evoked potentials and MRI.
Topics: Adolescent; Azathioprine; Cyclophosphamide; Demyelinating Diseases; Diffuse Cerebral Sclerosis of Sc | 1995 |
Successful treatment of neuropathies in patients with diabetes mellitus.
Topics: Aged; Azathioprine; Cyclophosphamide; Demyelinating Diseases; Diabetes Mellitus, Type 1; Diabetes Me | 1995 |
Clinical and radiological features of two cases of tacrolimus-related posterior leukoencephalopathy in living related liver transplantation.
Topics: Adult; Azathioprine; Brain Diseases; Cyclosporine; Demyelinating Diseases; Drug Therapy, Combination | 1998 |
Interferon alpha-2a therapy and pregnancy. Report of a case of chronic inflammatory demyelinating polyneuropathy.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Chronic Disease; Demyelinating Diseases; Female; Human | 1998 |
A case of chronic sensory demyelinating neuropathy responding to immunotherapies.
Topics: Azathioprine; Demyelinating Diseases; Humans; Immunotherapy; Male; Middle Aged; Nervous System Disea | 1992 |
[Immunomodulator therapy of chronic inflammatory demyelinating polyradiculoneuropathy].
Topics: Adjuvants, Immunologic; Adult; Azathioprine; Chronic Disease; Demyelinating Diseases; Female; Humans | 1991 |
Sclerosing hepatitis and azathioprine.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Demyelinating Diseases; Humans; Male | 1986 |
Paraproteinemia associated with demyelinating polyneuropathy or myositis: treatment with plasmapheresis and immunosuppressive drugs.
Topics: Azathioprine; Cyclophosphamide; Demyelinating Diseases; Female; Humans; Immunosuppressive Agents; Ma | 1985 |
Neurology and neuropathology of immunosuppressive therapy and acquired immunological deficiency.
Topics: Adolescent; Adult; Agammaglobulinemia; Aspergillus; Azathioprine; Brain; Brain Diseases; Candida; Ce | 1971 |
Multiple sclerosis: reticulum cell sarcoma of the nervous system in a patient treated with immunosuppressive drugs.
Topics: Adrenocorticotropic Hormone; Adult; Autopsy; Azathioprine; Biopsy, Needle; Brain Neoplasms; Cortison | 1974 |
Progressive multifocal leukoencephalopathy after renal transplantation. Demonstration of Papova-like virions.
Topics: Adult; Autopsy; Azathioprine; Brain; Demyelinating Diseases; Encephalitis; Female; Gliosis; Humans; | 1971 |